FIELD: bioengineering.
SUBSTANCE: invention relates to the use of the compound having formula
to stabilise a hypoxia induced factor-2 alpha (HIF-2α), for the reduced regulation of phosphoglycerate kinase (PGK) in a cell, and for the increased regulation of the release from the cell of a dissoluble receptor-1 of a vascular endothelial growth factor (sVEGF-1).
EFFECT: higher efficiency of the compositions use.
13 cl, 15 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROLYL HYDROXYLASE INHIBITORS | 2010 |
|
RU2518071C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| PROLYL HYDROXYLASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2429226C9 |
| COMPOSITIONS AND METHODS OF TREATING ANAEMIA | 2014 |
|
RU2705206C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| INHIBITION OF DISSEMINATION OF TUMOUR USING Bv8 OR G-CSF ANTAGONISTS | 2010 |
|
RU2567803C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| BENZOQUINONE E3330 DERIVATIVE IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR TREATING CANCER AND ANGIOGENESIS | 2008 |
|
RU2510270C2 |
| ANTISENSE OLIGONUCLEOTIDES TO HIF-1-ALPHA | 2017 |
|
RU2753517C2 |
